Borregaard ASA
BRRDF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.5B
Close$
$10.90
27.8% downside
Current Fair Value
27.8% downsideOvervalued by 27.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.50 Billion |
|---|---|
| Enterprise Value | $3.36 Billion |
| Annual dividend | $0.51 |
| Dividend yield | 3.05% |
| Earnings per Share | $6.21 |
| Beta | 0.57 |
| Outstanding Shares | 99,662,162 |
Return
| Return on Equity | 4.43% |
|---|---|
| Return on Assets | 2.69% |
| Return on Invested Capital | 15.32% |
Valuation & Multiples
| P/E Ratio | 57.63 |
|---|---|
| PEG | 110.99 |
| Price to Sales | 0.19 |
| Price to Book Ratio | 0.25 |
| Enterprise Value to Revenue | 0.43 |
| Enterprise Value to EBIT | 2.68 |
| Enterprise Value to Net Income | 12 |
| Total Debt to Enterprise | 0.66 |
| Debt to Equity | 0.36 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS
$0.31
Est. $0.22Revenue
$196.81 M
Est. $203.71 MNext Earnings Call
Expected Date
February 3, 2027
EPS Estimate
$0.19
Consensus analyst estimateRevenue Estimate
$188.34 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Borregaard ASA
1,228 employees
CEO: Tom Erik Foss-Jacobsen
Borregaard ASA engages in the development, production, and marketing of specialized biochemicals and biomaterials in Norway, rest of Europe, Asia, the United States, and internationally. It operates in three segments: BioSolutions, BioMa...